Hercules Capital, Inc. (HTGC) - 2025 Annual Report (10-K) Summary
Business Context and Reporting Period
This summary covers the fiscal year ended December 31, 2025. Hercules Capital, Inc. is an internally managed, non-diversified Business Development Company (BDC) and Regulated Investment Company (RIC). The company focuses on providing senior secured loans, primarily "Structured Debt" (debt with equity/warrant features), to high-growth, venture capital-backed technology and life sciences companies. As of December 31, 2025, the company managed approximately $5.7 billion in assets, including its own portfolio and third-party funds managed by its Adviser Subsidiary.
Key Financial Metrics
| Metric | 2025 | 2024 |
|---|---|---|
| Total Investment Portfolio (Fair Value) | $4,466.6 million | $3,660.0 million |
| Total Investment Income | $532.5 million | $493.6 million |
| Net Investment Income | $341.7 million | $325.8 million |
| Net Increase in Net Assets from Operations | $339.7 million | $263.0 million |
| Net Asset Value (NAV) per Share | $12.13 | $11.66 |
| Weighted Average Debt Outstanding | $2,051.2 million | $1,709.5 million |
| Weighted Average Cost of Debt | 5.0% | 5.0% |
| Asset Coverage Ratio (Excluding SBA) | 212.1% | 211.5% |
| Portfolio Core Yield (Non-GAAP) | 12.5% | 13.5% |
Material Changes vs. Prior Period
- Portfolio Growth: The total investment portfolio increased by approximately 22% to $4.47 billion, driven by net fundings of $1.68 billion and a net unrealized appreciation of $38.8 million.
- Income Growth: Total investment income rose 8% to $532.5 million, primarily due to an increase in the weighted average principal outstanding and higher dividend income from the Adviser Subsidiary. This was partially offset by a decline in core yield due to lower benchmark interest rates.
- Realized Losses: The company reported a net realized loss of $40.8 million in 2025, compared to $31.7 million in 2024. This included write-offs related to restructurings (e.g., Khoros, LLC) and sales of equity positions, offset by gains from sales of equity in companies like Axsome Therapeutics and BridgeBio Pharma.
- Debt Structure: The company issued $287.5 million in 2028 Convertible Notes and $350.0 million in June 2030 Notes during 2025. It also fully repaid $170 million in notes maturing in 2025 (February, June, and June 3-Year notes).
- Portfolio Composition: The portfolio remains concentrated in five sectors: Application Software (24.3%), Drug Discovery & Development (23.3%), Healthcare Services (18.8%), System Software (10.6%), and Consumer & Business Services (10.1%).
Guidance, Outlook, and Risks
Management Commentary: Management believes the portfolio is well-positioned to manage the current macroeconomic environment, noting that 97.9% of the debt portfolio is floating-rate with floors, providing insulation against declining rates. The company continues to focus on originating investments in resilient technology and life sciences sectors.
Risks and Contingencies:
- Concentration Risk: The portfolio is heavily concentrated in technology and life sciences. A downturn in these specific sectors could materially impact financial results.
- Liquidity and Prepayments: The company received $811.2 million in early principal repayments in 2025. Reinvestment of these proceeds at lower yields could negatively impact future returns.
- Valuation Uncertainty: Approximately 97.4% of total assets are Level 3 investments valued in good faith by the Board's Valuation Committee, introducing subjectivity to the reported NAV.
- Regulatory Constraints: As a BDC and RIC, the company is subject to asset coverage requirements (minimum 150%) and distribution requirements (90% of taxable income) which may limit operational flexibility.
Key Facts for Investor Verification
- NAV vs. Market Price: Verify the current trading price of HTGC relative to the reported NAV of $12.13 to assess the discount/premium.
- Dividend Sustainability: Confirm that the declared quarterly distribution of $0.47 per share (including supplemental) is fully covered by taxable income and that the company maintains sufficient liquidity to meet RIC distribution requirements without selling assets at distressed prices.
- Debt Maturity Wall: Review the maturity schedule of the $2.31 billion in outstanding debt, noting significant maturities in 2026 (March A/B Notes, September Notes) and the refinancing risk associated with them.
- Portfolio Credit Quality: Monitor the weighted average investment grading (2.20 as of year-end) and the percentage of assets in Grade 3, 4, or 5 status, which increased slightly in the lower grades compared to 2024.
- Unfunded Commitments: Note the $385.6 million in available unfunded commitments, which represent potential future cash outflows if portfolio companies draw down on their facilities.